NCT00112229View on ClinicalTrials.gov

Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

August 31, 2011

Study Completion Date

June 30, 2012

Conditions
Melanoma
Interventions
BIOLOGICAL

group 1

Melan-A analog peptide + CpG + Montanide

BIOLOGICAL

group 2

Melan-A natural peptide + CpG + Montanide

BIOLOGICAL

group 3

Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide

BIOLOGICAL

group 4

Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide

Trial Locations (1)

1011

Ludwig Institute for Cancer Research + Multidisciplinary Oncology Center at the Centre Hospitalier Universitaire Vaudois, Lausanne

Sponsors
All Listed Sponsors
collaborator

Ludwig Institute for Cancer Research

OTHER

lead

Centre Hospitalier Universitaire Vaudois

OTHER